Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01659853 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
A Phase 3 study of Rosacea and Erythema, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT01659853 is a Phase 3 study of Rosacea and Erythema that has completed, run by Galderma R&D. The registered enrollment target is 70 participants, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (71% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01659853, a Phase 3 study of Rosacea and Erythema, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily versus azelaic acid gel 15% applied topically twice daily in subjects with moderate to severe facial erythema of rosacea.
Interventions
- DRUG CD07805/47 gel 0.5%/CD07805/47 Vehicle
- DRUG azelaic acid gel 15%
Study Locations (4)
Indiana
- Hudson Dermatology - Evansville
Kentucky
- Dermatology Specialists Research, LLC - Louisville
Texas
- DermResearch, Inc - Austin
Virginia
- The Education & Research Foundation, Inc. - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01659853
The ClinicalTrials.gov registry entry for NCT01659853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (71% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which CD07805/47 gel 0.5%/CD07805/47 Vehicle is the first listed.
NCT01659853 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Indiana, Kentucky, Texas.
Frequently Asked Questions
What is clinical trial NCT01659853 about?
NCT01659853 is a clinical study titled "Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea". The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily versus azelaic acid gel 15% applied topically twice daily in subjects with moderate to severe facial erythema of rosacea.
What is the current status of trial NCT01659853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2012-09. Estimated completion is 2012-12.
What conditions does trial NCT01659853 study?
This clinical trial studies the following conditions: Rosacea, Erythema.
What interventions are being tested in trial NCT01659853?
The interventions under investigation include: CD07805/47 gel 0.5%/CD07805/47 Vehicle (DRUG), azelaic acid gel 15% (DRUG).
Who is sponsoring clinical trial NCT01659853?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01659853 being conducted?
This trial has 4 study locations across Indiana, Kentucky, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
COMPLETED · Phase 3
-
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
COMPLETED · Phase 3
-
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.